Drug Patent Watch
MAY 19, 2024
ADASUVE (loxapine) Alexza pharms Patent: 9,370,629 Expiration: May 20, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.
FDA Law Blog: Drug Discovery
MAY 19, 2024
By Sarah Wicks — On May 21, 2024, the EveryLife Foundation for Rare Diseases (ELF) will host a Scientific Workshop at the National Press Club in Washington, D.C. aimed at identifying and characterizing the challenges in developing therapies for ultra-rare diseases and conditions that affect exceedingly small populations. The workshop will drive in-depth discussions from leaders across federal agencies, the patient advocacy community, industry, academia and policy to examine the current state of
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drugs.com
MAY 19, 2024
SUNDAY, May 19, 2024 -- If you suddenly find yourself craving food or drink right before you head to bed, one expert suggests you steer clear of big meals and caffeine."From a sleep standpoint, you shouldn't eat a big meal at 8 p.m. if you plan to.
Drug Patent Watch
MAY 19, 2024
Annual Drug Patent Expirations for ADASUVE Adasuve is a drug marketed by Alexza Pharms and is included in one NDA. It is available from one supplier.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
MAY 19, 2024
This chart shows the pharmaceutical companies with the most patents in Lithuania.
Expert insights. Personalized for you.
59 
Let's personalize your content